Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factors inhibiting IFN activity

H Schellekens1, P H van der Meide, P von Wussow

  • 1Diagnostic Centre SSDZ, Delft, The Netherlands.

Biotherapy (Dordrecht, Netherlands)
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interferon Beta: From Molecular Level to Therapeutic Effects.

International review of cell and molecular biology·2016
Same author

The value of non-human primates in the development of monoclonal antibodies.

Nature biotechnology·2013
Same author

The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies.

Regulatory toxicology and pharmacology : RTP·2013
Same author

The cost-effectiveness of periodic safety update reports for biologicals in Europe.

Clinical pharmacology and therapeutics·2013
Same author

A framework for improving the quality of care for people with psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2012
Same author

The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies.

Clinical pharmacology and therapeutics·2011
Same journal

Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Elevated serum level of thioredoxin in patients with hepatocellular carcinoma.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Contribution of cytokines on the suppression of lung metastasis.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Levamisole and interleukin-2 for advanced malignancy.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.

Biotherapy (Dordrecht, Netherlands)·1999
See all related articles

Naturally occurring and therapy-induced antibodies can inhibit interferon (IFN) activity, impacting treatment efficacy. Understanding these inhibitors is crucial for managing autoimmune diseases and allograft rejections.

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Interferons (IFNs) are critical for immune responses but their activity can be inhibited by various factors.
  • These inhibitory factors include naturally occurring antibodies, therapy-induced antibodies, and other naturally occurring inhibitors.
  • The clinical significance of these inhibitors, particularly therapy-induced antibodies, has remained largely unclear.

Purpose of the Study:

  • To explore the factors that inhibit interferon activity.
  • To investigate the clinical significance of naturally occurring and therapy-induced antibodies against interferons.
  • To review potential therapeutic strategies targeting interferon receptor interactions.

Main Methods:

  • Review of existing literature on interferon inhibitors and antibody formation.

Related Experiment Videos

  • Analysis of antibody reactivity in naturally occurring versus therapy-induced cases.
  • Examination of animal studies demonstrating the efficacy of targeting interferon receptor interactions.

    • Main Results:

    • Naturally occurring antibodies exhibit broader reactivity than therapy-induced ones.
    • Antibody formation in chronic hepatitis C patients correlates with relapse.
    • Animal studies show that targeting IFN receptor interactions, using soluble IFN-gamma receptor or monoclonal antibodies to IFN-alpha receptor, can prevent autoimmune diseases and allograft rejection.

    Conclusions:

    • Antibodies against interferons, both naturally occurring and therapy-induced, play a significant role in modulating IFN activity and clinical outcomes.
    • Targeting interferon receptor interactions shows promise for therapeutic interventions in autoimmune diseases and transplantation.
    • Further research is needed to elucidate the structure and clinical significance of naturally occurring IFN inhibitors.